Products
Nisevokitug Biosimilar Monoclonal Antibody (TGF-β1 / TGF-β2) for Research
Cat No.: GMP-Bios-INN-1301
Anti-TGFB1/TGFB2 therapeutic antibody (Pre-made Nisevokitug biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Nisevokitug (development code NIS-793) is a monoclonal antibody targeting TGF-beta1 (TGFB1). It is developed by Novartis for Pancreatic cancers, Colorectal cancers, Myelodysplastic syndromes et al. in Phase III development.
Order Information
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. →
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-INN-1301-1mg | 1mg | 3090 |
| GMP-Bios-INN-1301-10mg | 10mg | |
| GMP-Bios-INN-1301-100mg | 100mg | |
| GMP-Bios-INN-1301-xmg | ≥100mg |
Product Details
| Products Name (INN Index) | Pre-Made Nisevokitug biosimilar, Whole mAb, Anti-TGFB1/TGFB2 Antibody: Anti-TGF Beta 1/TGFB1/Transforming growth factor beta-1 proprotein/CED therapeutic antibody |
| INN Name | Nisevokitug |
| Target | TGFB1/TGFB2 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1+2+3 Isotype | G2 |
| VD LC | Lambda |
| Highest_Clin_Trial (Jan '20) | Phase-III |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2022 |
| Year Recommended | 2023 |
| Companies | Novartis |
| Conditions Approved | na |
| Conditions Active | Pancreatic cancers;Colorectal cancers;Myelodysplastic syndromes;Pancreatic ductal adenocarcinoma;Metastatic cancers |
| Conditions Discontinued | na |
| Production | na |
| Development Tech | na |
